Corvus Pharmaceuticals board member Ian T. Clark to resign, effective July 22, 2026
Corvus disclosed in an SEC filing that Clark notified the company of his plan to step down from the board after more than nine years of service.
Corvus Pharmaceuticals, Inc. reported in a Form 8-K dated July 22, 2026 that board member Ian T. Clark gave notice on July 21, 2026 that he plans to step down from the company's board of directors, with the resignation taking effect July 22, 2026. On July 21, 2026, Ian T. Clark delivered notice of his intention to resign from the board of directors (the "Board") of Corvus Pharmaceuticals, Inc. (the "Company"), effective as of July 22, 2026.1
In the filing, Corvus acknowledged Clark's service on the board, noting his tenure spanned more than nine years. The Company thanks Mr. Clark for his significant contributions to the Company during over nine years of Board service.1
The disclosure was made under Item 5.02 of the 8-K, which covers departures of directors or officers and related executive appointments. The filing does not state a reason for Clark's departure, nor does it name a successor or describe any changes to board composition beyond his exit.
The report was signed by Leiv Lea, Corvus's Chief Financial Officer, on July 22, 2026. Corvus Pharmaceuticals is headquartered at 901 Gateway Boulevard, Third Floor, South San Francisco, California, and its common stock trades on the Nasdaq Global Market under the ticker CRVS.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.